FIELD: organic chemistry.
SUBSTANCE: group of inventions includes a compound of formula I, a compound of formula II, 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them, method of treatment and use based on 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione. In formula I R1 represents H, Br, C1-C6 alkyl or phenyl; R2 is H, halogen or CH3-; R3 is H, hydroxyC1-C6 alkyl-, hydroxyC1-C6 alkoxy-, C1-C6 alkoxy, fluoroC1-C6 alkoxy, C3-C6 cycloalkyl or (C3-C6 cycloalkyl)C1-C6 alkoxy-; R4 is phenyl substituted with 1, 2 or 3 substituents, independently selected from halogen, C1-C6 alkyl, C1-C6 alkylthio, fluoroC1-C6 alkylthio, fluoroC1-C6 alkyl, C1-C6 alkoxy, fluoroC1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl-C(=O)-. In formula II, R1 is H, Br, C1-C6 alkyl or phenyl; R2 is H, halogen or CH3-; R3 is H, hydroxyC1-C6 alkyl-, hydroxyC1-C6 alkoxy-, C1-C6 alkoxy, fluoroC1-C6 alkoxy, C3-C6 cycloalkyl or (C3-C6 cycloalkyl)C1-C6 alkoxy-; Ra and Rb are independently selected from halogen, C1-C6 alkyl, C1-C6 alkylthio, fluoroC1-C6 alkyl, C1-C6 alkoxy, fluoroC1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl-C(=O)-.
EFFECT: derivatives of 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione, having MEK inhibitory activity.
36 cl, 5 dwg, 8 tbl, 77 ex
Title | Year | Author | Number |
---|---|---|---|
4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS SUITABLE AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | 2018 |
|
RU2804468C2 |
QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
COMPOUND AS WNT SIGNAL INHIBITOR, ITS COMPOSITIONS AND APPLICATION | 2012 |
|
RU2627712C2 |
BICYCLIC PYRIDINES AND ANALOGUES AS SIRTUIN MODULATORS | 2010 |
|
RU2550821C2 |
SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
THIENOPYRROL DERIVATIVES FOR APPLICATION FOR TARGETING PROTEINS, COMPOSITIONS WITH SAID DERIVATIVES, METHODS AND APPLICATIONS | 2017 |
|
RU2771166C2 |
TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
Authors
Dates
2024-09-03—Published
2022-03-30—Filed